ellure glp 1 GLP-1 Up Support your healthy weight management goals with this simple GLP-1 Elevate®

Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

GLP-1s should only be used under the supervision of a licensed healthcare provider because they may cause gastrointestinal side effects, gallbladder disease, and, rarely, pancreatitis or thyroid C-cell tumors

Common side effects include nausea, diarrhea, constipation, vomiting and indigestion

A licensed clinician reviews your health history, confirms that the infusion is appropriate, and answers any questions you may have